Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported first quarter 2023 revenues of $380.8 million, marking a 1.1% increase year-over-year on a reported basis and 4.6% growth organically. GAAP earnings per diluted share were $0.29, down from $0.39 in the previous year, with adjusted earnings remaining steady at $0.74. The company reaffirmed its full-year revenue guidance of $1,602 to $1,620 million and adjusted EPS guidance of $3.43 to $3.51. Segment performance showed $248.1 million in revenues from Codman Specialty Surgical, while Tissue Technologies generated $132.7 million. Key highlights include strong demand across product lines and a successful launch of new products. The company also strengthened its balance sheet and returned value to shareholders through a $150 million share repurchase program.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its first quarter 2023 financial results on April 26, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the earnings.
Investors can access the live webcast on the company's investor website. A replay of the call will be available afterward. Integra is renowned for its regenerative tissue technologies and neurosurgical solutions, providing high-quality products that support optimal patient care.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its 2022 financial results, revealing fourth quarter revenues of $398.0 million, a 1.8% decrease year-over-year, but a 2.9% organic growth. GAAP earnings per diluted share rose to $0.63 from $0.53 in Q4 2021. For the full year, revenues reached $1,557.7 million, a 1.0% increase, with GAAP EPS at $2.16. The company provided guidance for 2023, expecting revenues of $1,602 million to $1,620 million and adjusted EPS between $3.43 and $3.51, indicating optimism for growth as markets recover from COVID-19 impacts.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its fourth quarter 2022 financial results on February 22, 2023, before the market opens. A conference call with the management team is scheduled for 8:30 a.m. ET on the same day. This event will be accessible via a live webcast on the company's investor website. Integra is recognized as a leader in regenerative tissue technologies and neurosurgical solutions, providing a wide range of high-quality products to enhance patient care. Investors can find further details and register for the call on their official site.
Campbell Soup Company (NYSE:CPB) announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective February 6. Anderson will oversee the finance function including controllership, corporate financial planning, and analysis, among other areas. She succeeds Mick Beekhuizen, who transitioned to President of the Meals & Beverages division. Anderson joins from org value="NASDAQ-NMS:IART"Integra LifeSciences where she served as CFO since 2019. With a background in diverse industries and a strong financial acumen, her leadership is expected to enhance Campbell's growth and performance.